As a result, PARP inhibitors that block the addition of ADPr and PAR chains, and that trap PARP enzymes on DNA, are synthetic-lethal with the primary defect and therefore commonly used for treatment of BRCA-deficient cancers. Here, PARP1 is linked to cancer.